You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 275 No. 2, January 10, 1996 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Grand Rounds at the Clinical Center of the National Institutes of Health
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Ocular Manifestations of AIDS

Scott M. Whitcup, MD

JAMA. 1996;275(2):142-144.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

SELECTED CASE

A 17-year-old patient with hemophilia A was diagnosed with transfusion-acquired human immunodeficiency virus (HIV) infection in 1987. Antiretroviral therapy for diminishing CD4 cell counts included zidovudine for 3 years followed by didanosine and lamivudine (known then as 3TC). An initial ophthalmic screening examination in December 1992 revealed visual acuity of 20/20 in each eye, and retinal examination showed several nerve fiber layer infarcts (cotton-wool spots) in the left eye. In November 1993 the patient had no visual complaints, but on routine eye examination, visual acuity was 20/32 in the right eye and 20/25 in the left eye. Retinal examination revealed bilateral cytomegalovirus (CMV) retinitis (Figure), and the patient was started on intravenous ganciclovir at a dose of 5 mg/kg twice daily. Other medications included rifabutin (150 mg daily), captopril (12.5 mg twice a day), digoxin (0.37 mg daily), megestrol acetate (40 mg three times a day), lamivudine (175 . . . [Full Text PDF of this Article]


Author Affiliations

From the Clinical Branch, National Eye Institute, National Institutes of Health, Bethesda, Md.


Footnotes

This article is one of a series addressing emerging and reemerging global microbial threats.

Reprint requests to National Eye Institute, 10 Center Dr, Bldg 10, Room 10N 202, Bethesda, MD 20892-1858 (Dr Whitcup).

Grand Rounds at the Clinical Center of the National Institutes of Health section editors: John I. Gallin, MD, the Clinical Center of the National Institutes of Health, Bethesda, Md; David S. Cooper, MD, Contributing Editor, JAMA.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.